Estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) are currently recognized as biomarkers affecting treatment decisions in BC patients (Voduc et al., 2010; El-Deiry et al., 2019). This evidence concerns the gene ERBB2 and breast cancer.